BiotechTube
Home/Pipeline/Undisclosed Candidate

Undisclosed Candidate

Not Specified

Pre-clinicalActive

Key Facts

Indication
Not Specified
Phase
Pre-clinical
Status
Active
Company
Brenus Pharma

About Brenus Pharma

Brenus Pharma is a privately held, clinical-stage biotech founded in 2020 in Lyon, France. The company has developed a novel platform that creates 'ghost cell' immunotherapies designed to expose the broadest panel of cancer-associated antigens to the immune system, aiming to overcome the limitations of current immunotherapies in solid tumors. With €30M in strategic funding, Brenus is advancing its lead candidate, STC-1010, into Phase I/II trials for metastatic colorectal cancer, targeting a significant patient population with limited options. The company is led by a seasoned team with deep experience in oncology, drug development, and entrepreneurship.

View full company profile

Therapeutic Areas

OncologyImmunology

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved